Compare Indonesia Energy Corporation Limited (INDO) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Indonesia Energy Corporation Limited vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Indonesia Energy Corporation Limited trades at $2.66 (market cap $42.31M), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Maravai LifeSciences Holdings Inc. Class A Common Stock is far larger — about 23× Indonesia Energy Corporation Limited's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Indonesia Energy Corporation Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Indonesia Energy Corporation Limited for 24 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| INDO | MRVI | |
|---|---|---|
Market Cap | $42.31M | $972.90M |
Volume | 193,916 | 4,325,710 |
Sector | Energy | Health |
52-Week High | $6.74 | $9.00 |
52-Week Low | $2.49 | $2.83 |
Typical Hold Time | 24 Days | 0 Days |
Enterprise Value | $37.25M | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INDO trades at $2.75 with minimal daily movement (+0.36%). The stock shows bearish technical signals despite unanimous analyst buy ratings. Fundamentally, the company faces significant challenges with negative profit margins (-152.72% net income margin) and consistent quarterly losses, though recent oil discoveries at the K-29 well provide operational optimism. Cash flow remains dependent on financing activities to offset negative operational cash flow.
While analyst consensus remains bullish with 100% buy ratings, the stock presents high-risk exposure due to persistent unprofitability and negative cash generation. The company's exploration success offers potential upside, but investors face substantial execution risk and financial instability in the near term.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Indonesia Energy Corporation Limited
Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
